Pro-Dex Inc (PDEX) FinancialsPDEXPro-Dex Inc

Pro-Dex Inc (PDEX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medical devices, accounting for 81.4% of total sales, equivalent to $16.24M. Other significant revenue streams include Repairs and NRE & Prototypes. Understanding this composition is critical for investors evaluating how PDEX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Pro-Dex Inc maintains a gross margin of 33.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 17.10%, while the net margin is 14.82%. These profitability ratios, combined with a Return on Equity (ROE) of 26.48%, provide a clear picture of how effectively PDEX converts its operational activities into shareholder value.

In the context of the broader market, PDEX competes directly with industry leaders such as INGN and STIM. With a market capitalization of $203.14M, it holds a significant position in the sector. When comparing efficiency, PDEX's gross margin of 33.35% stands against INGN's 45.51% and STIM's 51.06%. Such benchmarking helps identify whether Pro-Dex Inc is trading at a premium or discount relative to its financial performance.

Pro-Dex reported a net income of $13.66 million for FY 2026, translating to $4.12 per share, a remarkable 52% increase from the previous year. The gross margin for Q4 FY 2026 was 34.75%, indicating strong profitability. The company has shown consistent revenue growth, with Q4 FY 2026 net sales of $20.41 million, a 17% increase year-over-year.